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rent serum biomarkers are not sensitive enough for diagnosis. With the aim of finding proteins
associated with sepsis, serum protein profile was compared between patients and healthy do-
nors and serum classical inflammatory proteins were analyzed in both groups.
Methods: Serum protein profiles were characterized by two-dimensional electrophoresis
(2DE). Identification of the proteins was carried out by mass spectrophotometry and their vali-
dation was performed by Enzyme-Linked-ImmunoSorbent Assay (ELISA) in a cohort of 85 pa-
tients and 67 healthy donors. Seven classical inflammatory proteins were analyzed in the
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466 S. Garcia-Obregon et al.rich-type-1 (sCD163), tumor-necrosis factor receptor superfamily-member-6 (sFas),
hemeoxigenase-1 decycling (HO-1), interleukin-6 (IL-6), interleukin-18 (IL-18) and intercellular
adhesion-molecule-1 (sICAM-1).
Results: After 2DE, 20 significantly differently expressed spots were identified by mass spec-
trometry analysis, revealing deregulation of six different proteins upon sepsis and 50% were
validated by ELISA: Antithrombin-III (AT-III), Clusterin (CLUS) and Serum amyloid A-1 (SAA-1).
Serum concentration of AT-III and CLUS was significantly lower in patients0 serum, whereas
SAA-1 showed higher values in septic patients. Serum concentration of the seven inflammatory
proteins was significantly increased in septic patients. Functional analysis of the ten deregu-
lated proteins revealed an enrichment of proteins related mainly to the activation of the im-
mune response.
Conclusion: We have identified a panel of ten potential sepsis marker proteins biologically con-
nected and validated in a large number of patients, whose analysis could be considered as a
complementary tool for the diagnosis of sepsis.
Copyright ª 2017, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Pathogenesis of sepsis is poorly understood and remains one
of the major health problems of the current medicine, due
to its high associated mortality1,2 and its elevated economic
burden at intensive care units.3,4 Physicians usually make
their diagnosis based on a set of clinical symptoms but
diagnosis is challenging even following the guidelines pub-
lished by Surviving Sepsis Campaign Consortium5 and Soci-
ety of Critical Care Medicine Consensus Conferences.6e9
Sepsis has been recently re-defined as a life-threatening
organ dysfunction caused by a deregulated host response to
infection.7,8 In this context, sepsis and infection are
different as sepsis implies both a deregulated host response
and the presence of organ dysfunction.7 Clinical criteria for
identifying septic patients by using Sequential (Sepsis
related) Organ Failure Assessment (SOFA) have recently
been published. An increase of SOFA 2 is associated with
sepsis, and septic shock is defined as a subset of sepsis in
which despite fluid resuscitation, the patient requires va-
sopressors to maintain arterial pressure 65 mm Hg and
serum lactate 2 mmol/l.8 Despite these criteria, clinical
presentation of sepsis/septic shock is often heterogeneous
and symptoms are usually influenced by many factors such
as host susceptibility or the virulence and bioburden of the
pathogen.10 An accurate and early diagnosis is crucial for
prognosis and prompt therapy based on supportive care and
antibiotics.
Although some markers (C-reactive protein, procalcito-
nin, among others) are currently in use in clinical practice
for sepsis, they are not sensitive enough for diagnosis.11
Furthermore, due to the complexity of the sepsis disease
a single biomarker may not reflect accurately a septic pa-
tient’s status. In this context, definition of specific markers
panels may help the physician to improve clinical decisions
for septic patients.
Analysis of specific protein patterns occurring in bio-
fluids has a great relevance for both understanding the
pathogenesis and definition of disease markers. Among
biological fluids, serum is one of the best candidates andmay provide greater knowledge about molecular alter-
ations caused by sepsis leading to characterization of bio-
markers related to its diagnosis.12,13
With the aim of finding proteins associated with the
disease, in this work, two-dimensional electrophoresis
(2DE) and Enzyme-Linked ImmunoSorbent Assay (ELISA)-
based analysis were carried out using septic patients’
serum. A panel of ten proteins was set-up and validated in a
cohort of 85 patients and 67 healthy donors, linking dif-
ferential protein expression to the activation of immune
response and inflammatory processes, and defining a set of
potential sepsis markers whose analysis may eventually be
useful for decision-making in the clinical context.
Methods
This study was carried out at Hospital Universitario Cruces
between 2011 and 2015. Blood samples were obtained from
venous catheter in 85 patients (31 females, 54 males; me-
dian age: 62 years-old) diagnosed with sepsis/septic shock
according to diagnosis criteria set by the International
Sepsis Definitions Conference6e9 (sepsis associated with
organ dysfunction and/or tissue hypoperfusion, despite
adequate volume resuscitation, requiring vasopressors)
during the first hours after diagnosis, which means in early
stage of sepsis. Blood samples were taken through Vacu-
tainer venepuncture in 67 healthy donors (23 females, 44
males; median age: 50 years-old). Samples were allowed to
clot at room temperature and were centrifuged at 2000 rpm
for 20 min. Separated serum was stored at 80 C until
analysis. Patients were monitored until day 60 after sepsis.
Five patients died due to sepsis during the first 15 days and
other five patients were dead for other reasons during the
monitoring time.
Protocol was approved by Ethics Committee of the Bas-
que Country and all the patients provided written informed
consent. Serum samples from healthy donors were obtained
from the Basque Center for Transfusion and Human Tissues.
All the samples were initially processed and stored until
analysis in Basque Biobank for Research in accordance with
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ings. Study was performed according to Spanish Law
(Biomedical Research and Protection of Personal Data) and
Declaration of Helsinki.
In the initial proteomic study, five healthy donors (me-
dian age: 51 years-old) and five patients (median age: 58
years-old) affected with sepsis/septic shock were included.
Blood samples from patients were obtained during the first
24e48 h after diagnosis. Clinical features of the patients
enrolled in proteomic assessment are summarized in Table
1. Four patients were diagnosed with septic shock and one
with sepsis. In two patients, infections were confirmed by
microbiological analysis. Initial antibiotic treatment was
administered to all patients in the emergency department.
The five patients showed organ dysfunction, and three of
them presented dysfunction of two or more organs. How-
ever, all these patients survived.
For proteomic analysis, Proteominer Large Capacity Kit
(Bio-Rad Laboratories, Hercules CA, USA) was applied to the
ten serum samples in order to remove high-abundance
proteins such as albumin or IgG, because they tend to mask
those in lower abundance.14
Beginning with 2D-assay, protein samples (100 mg protein
each) were dissolved separately in rehydration buffer (7 M
urea, 2 M tiourea, 4%CHAPS, 1%DTT, 0.2%ampholytes and
bromophenol blue) including DeStreak TM (GE Healthcare,
Piscataway, NJ, USA) and ampholytes (Bio-Rad). In the next
step, samples were loaded individually in 11 cm pH 4e7
gradient IPG strips (Immobiline DryStrips, GE Healthcare) to
carry out the first dimension in Protean IEF-Cell (Bio-Rad).
Each IPG strip was submitted to the following IEF program:
passive rehydration for 14 h; 2 h at 150 V; 2.5 h at 8,000 V;
8,000 V until 25,000 V/h; 24 h at 500 V. After first dimen-
sion, strips were equilibrated with buffer-I (6 M Urea,
0.375 M TriseHCl, 2% SDS, 20% Glycerol, 2% DTT) with gentle
shaking for 5 min (twice), followed by a second equilibra-
tion with buffer-II (6 M de Urea, 0.375 M TriseHCl, 2%SDS,
20%Glycerol, 2.5% Iodoacetamide) with gentle shaking for
10 min (twice).
For the second dimension, IPG strips were placed in
contact with commercial acrylamide gels (Criterion XT
Precast Gel, Bio-Rad) for protein separation according to
their molecular weight. Gels were subjected to electro-
phoresis at 90 mA for 3 h, until the bromophenol blue frontTable 1 Clinical features of septic patients included in proteom
Age Sex Pathogen Source of in
Patient 1 58 Male E. coli Abdomen
Patient 2 57 Male Not detected Respiratory
Patient 3 48 Male S. Aureus Respiratory
Patient 4 60 Male Not detected Nephrology
Patient 5 64 Female Not detected Nephrology
a APACHE (Acute Physiology and Chronic Health Evaluation).
b SOFA (Sequential Organ Failure Assessment).reached the bottom of the gels. Gels were stained over-
night with SYPRO Ruby Protein Gel Stain (Bio-Rad) and
scanned by Image Scanner (Typhoon Trio, GE Healthcare).
Image analysis was performed with LUDESI Redfin-3 soft-
ware (www.ludesi.com). Spots with at least a 1.2-fold
abundance change and p < 0.05 were accepted as statis-
tically significant and selected for protein identification.
Mass spectrometry analysis were performed as described
elsewhere,15 with minor modifications. Protein digestion
was conducted following the protocol described by Shev-
chenko et al.,16 with minor variations. Gel spots were
digested with trypsin overnight at 37 C. After digestion,
supernatants were collected and acidic peptides were
extracted with trifluoroacetic acid. Samples were dried out
in a Christ RVC C2-25 speed vac concentrator (Christ GmbH,
Osterode, Germany) and submitted to MALDI-TOF/TOF
analysis as described in Anitua et al.,.15 When no confi-
dent identification was obtained with MALDI-TOF/TOF,
peptides were analyzed in an LTQ Orbitrap XL ETD mass
spectrometer (Thermo Scientific, Waltham, Massachusetts,
USA) coupled to a nanoACQUITY UPLC System (Waters,
Manchester, UK). A 30 min linear gradient of 3e50%
acetonitrile was used for the chromatographic runs.
Collision-induced dissociation was used for the generation
of fragmentation spectra. Precursors with charge states of
2 and 3 were specifically selected and excluded from
further analysis during 60 s using the dynamic exclusion
feature. Searches were conducted against human Swis-
sprot/Uniprot database with Mascot search engine (www.
matrixscience.com), under standard search parameters
and tolerances for each of the mass spectrometers used.
Carbamidomethylation of cysteines and oxidation of
methionines were considered as fixed and variable
modifications respectively.
Deregulated proteins found in serum by the proteomic
study were validated by ELISA assays in cohorts of 85 pa-
tients and 67 healthy donors. Given the importance of in-
flammatory processes in sepsis,17 the same serum samples
from septic patients and healthy individuals were tested for
a set of seven inflammatory proteins by ELISA assays:
hemeoxigenase-1 decycling (HO-1), interleukin-6 (IL-6),
interleukin-18 (IL-18), soluble intercellular adhesion-
molecule-1 (sICAM-1), soluble interleukin-2 receptor
alpha-chain (sCD25), soluble scavenger receptor cysteine-ic study.
fection APACHEa SOFAb Organ dysfunction
19 10 Cardiovascular
Haematological
Hepatic
tract 18 8 Cardiovascular
Renal
Respiratory
tract 14 12 Cardiovascular
Respiratory
Urinary tract 21 7 Cardiovascular
Urinary tract 17 4 Cardiovascular
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ceptor superfamily-member 6 (sFas). In all cases, ELISA
assays were performed using commercial kits and following
the manufacturer’s procedures (Abnova GmbH, Germany;
R&D Systems, Minneapolis, MN, USA; USCN Life Science Inc.
Houston, TX, USA). Due to samples availability not all the
proteins were tested in the complete cohorts of patients
and healthy donors. Descriptive analysis for ELISA concen-
tration results was performed with statistical package SPSS
ver.22.0 (SPSS Inc. 2003, Chicago, IL, USA). To test signifi-
cant differences in concentrations of proteins between
patients and controls, ManneWhitney U test and indepen-
dent media test for unrelated samples were performed. p
values < 0.05 were accepted as statistically significant.
Analysis of the cellular and biological features of
deregulated proteins was carried out using the DAVID
functional annotation tool from the NIH.18,19 A Functional
Annotation Clustering analysis was conducted for a clearer
outcome of the relevant non/redundant results. Only pro-
cesses enriched with a Fisher Exact test p < 0.05 were
considered for further discussion.Results
Two-dimensional gels profile of healthy and septic
patients
Protein extracts from serum samples obtained from five
healthy volunteers and five septic patients were loaded
individually onto the 2DE system. Differential protein 2DE
gel profiles between healthy donors and septic patients are
shown in Fig. 1. More than 600 spots were detected in each
gel, however, only 22 were considered as significantly
deregulated between healthy donors and patients (1.2-fold
abundance change and p < 0.05) by computational analysis
performed with LUDESI Redfin-3 software.
In order to identify proteins differentially expressed in
septic patients, spots were excised manually and subjected
to digestion before submission to mass spectrometry anal-
ysis. A total of 20 out of the 22 spots considered as signif-
icantly deregulated were successfully identified by MALDI-
TOF/TOF and LC-MS. The results for their deregulation and
identification are summarized in Table 2.
These results revealed the identity of seven different
deregulated proteins: Antithrombin-III (AT-III),
Apolipoprotein-E (Apo-E), Clusterin (CLUS), Complement
factor H-related-1 (FRH1), Filaggrin, Hemoglobin subunit
beta (Hb-b) and Serum amyloid A-1 (SAA-1). All these pro-
teins were related to inflammation and immune system,
with the exception of Filaggrin, which is associated with
epidermis20 and its presence in the gels was probably due to
contamination. For this reason, this protein was excluded
from the following validation process.
ELISA assay: Validation of proteomic assay and
study of a set of inflammatory proteins
Immune related proteins identified in the proteomic study
(AT-III, Apo-E, CLUS, FHR1, Hb-b and SAA-1) were analyzed
in a cohort of 85 patients and 67 healthy donors by ELISAassays. Fifty percent of the proteins identified in the pro-
teomic experiment were validated when patients and
controls were compared: AT-III, CLUS and SAA-1. Results are
shown in Table 3. Consistent with the results obtained in
2DE, SAA-1 showed higher values in patients’ serum,
whereas serum concentration of AT-III and CLUS was
significantly lower in septic patients. However, FRH1, ApoE
and Hbb did not show significant differences in serum
concentration levels between patients and controls when
they were validated in a cohort of 85 patients and 67
healthy donors by ELISA assays.
Given the importance of inflammatory processes in
sepsis, an additional panel of seven inflammation-related
serum factors (HO-1, IL-6, IL-18, sICAM sCD25, sCD163 and
sFAS) was also analyzed. The results are shown in Table 3
and as can be noted, all the seven inflammation-related
serum factors analyzed by ELISA were shown to be signifi-
cantly more abundant in patients’ serum.
In a next step, we evaluated if these ten deregulated
proteins (AT-III, CLUS, SAA-1, HO-1, IL-6, IL-18, sICAM
sCD25, sCD163 and sFAS) were different between dead
patients and survivors, and no significant differences were
found between both groups (data not shown).
Gene ontology analysis
Finally, a functional analysis of the ten proteins signifi-
cantly deregulated in septic patients (AT-III, CLUS, SAA-1,
HO-1, IL-6, IL-18, sCD25, sCD163, sICAM-1, and sFAS) was
carried out by using DAVID functional annotation tool in
order to better characterize in what processes they might
be involved. Results are summarized in Supplementary
Table 1. Consistent with the system under study, the
functional analysis of the deregulated proteins revealed an
enrichment of proteins mapping to the extracellular space
(pZ 2.51E-04) and related to the activation of the immune
response (p Z 6.56E-06), inflammatory response
(p Z 1.08E-05) and response to wounding (p Z 7.42E-05).
Given that proteins considered as significantly deregulated
in both the proteomics and ELISA approaches contribute to
these enrichments, the functional analysis underlines the
coherence between the results from both approaches and
points out their convergence in such processes and
functions.
Discussion
Characterization and proper diagnosis of sepsis patients
remains a challenge in current medicine. Complications
derived from septic processes very often have deleterious
consequences for patients and high economic costs.4 Thus,
a better knowledge of the molecular mechanisms underly-
ing sepsis may allow better diagnosis tools and the devel-
opment of new therapies against the disease. Serum
appears to be a suitable candidate for monitoring the sepsis
process, since its properties make it an affordable biofluid
that can be analyzed with ease and low cost procedures.12
2DE-based differential proteomics provides a better
understanding of the disease though the discovery of novel
disease markers. In this work we present the analysis and
validation of differentially expressed proteins upon sepsis.
Figure 1. Gels from controls (up) and patients (down). Numbers correspond to the spots accepted as statistically significantly
deregulated between controls and septic patients group (1.2-fold abundance change and p < 0.05).
Serum protein markers and their validation in sepsis 469Twenty differential spots were successfully identified, and
seven different proteins accounted for their deregulation,
revealing that the same protein was present in many of
these spots. This is a common phenomenon in 2DE-tech-
nology,21 since different post-translational modifications of
proteins, such as glycosylation, phosphorylation, among
many others or proteolytic processing, may alter their
electrophoretic properties. Thus, different forms of a pro-
tein may form different spots. Therefore, our results sug-
gest some kind of modification for AT-III, CLUS, and FHR1.
Elucidating the nature of these modifications, however,
surpasses the scope of this study.
The proteomic approach allowed us to identify seven
proteins, all of them related to inflammation and immune
system, except Filaggrin. Taking into account that samples
came from human serum and Filaggrin is associated with
epidermis,20 its presence may respond to a contaminated
spot. The big score and number of peptides of Filaggrin
could be explained by the fact that contaminants, often
relatively more abundant than proteins of interest, rendermore detectable peptides. For this reason, Filaggrin was
excluded from the validation process.
The other six identified proteins were potentially
interesting in sepsis research and the differential expres-
sion in septic serum was validated for three of them. The
inherent complexity of the serum 2DE-protein patterns
may in part explain this result. As mentioned before, 2DE
has the power of resolving protein isoforms when these
have different isoelectric points or molecular weights.
Therefore, some of the results obtained by 2DE may be
ascribed to certain modifications of a protein rather than
to its total amount. Thus, when analyzing the whole
amounts of these proteins, such as in ELISA assays, it is not
surprising that some of the results may not converge, since
different subsets of the protein may be analyzed in each of
them. This could be the case of proteins with complex 2D-
patterns, such as FHR1.
Nonetheless, the 2DE analysis led us to robust validation
of deregulation of three proteins in a large cohort of pa-
tients: AT-III, CLUS and SAA-1. In our study, serum
Table 2 Identification of deregulated spots in sepsis patients’ serum.
Spota Analysisb Ratioc p value Accessiond Namee Scoref # Peptidesg MW [kDa]h
7 MALDI-TOF 2.15 0.000 CLUS_HUMAN Clusterin 443 8 53.0
17 MALDI-TOF 12.74 0.045 SAA1_HUMAN Serum amyloid A-1 227 4 13.6
22 MALDI-TOF 1.71 0.009 ANT3_HUMAN Antithrombin-III 288 7 53.0
23 MALDI-TOF 2.72 0.019 APOE_HUMAN Apolipoprotein E 280 6 36.2
26 LC-MS 3.34 0.010 FHR1_HUMAN Complement factor H-related protein 1 193 6 37.6
35 MALDI-TOF 1.56 0.003 CLUS_HUMAN Clusterin 297 3 53.0
38 MALDI-TOF 2.19 0.004 ANT3_HUMAN Antithrombin-III 267 5 53.0
40 LC-MS 3.00 0.021 FHR1_HUMAN Complement factor H-related protein 1 101 3 37.6
47 LC-MS 2.60 0.023 FHR1_HUMAN Complement factor H-related protein 1 177 4 37.6
49 LC-MS 2.64 0.029 CLUS_HUMAN Clusterin 99 2 52.5
53 MALDI-TOF 1.78 0.010 ANT3_HUMAN Antithrombin-III 173 3 53.0
82 LC-MS 1.36 0.042 HBB_HUMAN Hemoglobin subunit beta 207 3 16.0
87 MALDI-TOF 3.19 0.000 CLUS_HUMAN Clusterin 183 3 53.0
92 MALDI-TOF 2.77 0.001 CLUS_HUMAN Clusterin 62 2 53.0
98 MALDI-TOF 1.66 0.003 CLUS_HUMAN Clusterin 119 2 53.0
126 MALDI-TOF 1.67 0.032 ANT3_HUMAN Antithrombin-III 242 6 53.0
143 MALDI-TOF 2.51 0.003 CLUS_HUMAN Clusterin 112 4 53.0
190 LC-MS 2.06 0.023 CLUS_HUMAN Clusterin 120 5 52.5
201 LC-MS 2.55 0.006 FILA_HUMAN Filaggrin 631 20 434.9
227 MALDI-TOF 3.12 0.000 CLUS_HUMAN Clusterin 260 4 53.0
a Spot: number of spot in the 2DE gel.
b Analysis: mass spectrometric analysis method providing the identification.
c Ratio: sepsis/control spot volume ratio.
d Accession: accession number for that protein in Uniprot knowledgebase.
e Name: protein name in Uniprot knowledgebase.
f Score: Mascot score.
g # Peptides: number of identified peptides matching to the protein.
h MW [kDa]: molecular weight of the protein expressed in kDa.
470 S. Garcia-Obregon et al.concentration of AT-III was significantly lower in septic
patients when compared with control group, in agreement
with previously reported data.22,23 Low level of AT-III in
serum is correlated with disseminated intravascular coag-
ulation, which is a common clinical complication in septic
patients.24 Therefore, AT-III could be considered as a po-
tential biomarker candidate in the diagnosis of sepsis. In
fact, the administration of AT-III has been assessed in some
clinical trials but its use continues to be controversial.25,26
On the other hand, SAA-1 is highly expressed in septic pa-
tients and revealed response to inflammation and tissue
injury. High levels of this protein have been associated with
chronic inflammatory diseases including atherosclerosis and
rheumatoid arthritis.27 Our results are in concordance with
previous studies where SAA proteins have been described as
promising biomarkers in the diagnosis of sepsis.28 CLUS have
been reported as a protein with a significant role in
inflammation and immune responses.29 However, its char-
acterization in sepsis is poorly documented. Our study
revealed low concentration of CLUS protein in serum from
septic patients in concordance with a recent study.30 On
the contrary, FHR1, Apo-E and Hb-b did not show differ-
ences in serum concentration between patients and con-
trols, which is not in agreement with some previous
authors.31,32
In addition to the proteomic analysis, seven inflamma-
tory proteins (HO-1, IL-6, IL-18, sCD25, sCD163, sICAM-1 and
sFas) were characterized and validated by ELISA in the
same cohort of individuals used for the validation of theproteomic results. The main reason for the lack of
inflammation-related proteins within the 2DE results is that
they are very likely out of the limit of detection of our
experimental setup and their detection was only affordable
using a targeted approach such as ELISA. Statistical analysis
revealed a significantly increased presence of these seven
proteins in patients’ serum. The increase in sFAS, HO-1 and
sICAM-1 in septic patients is in accordance with previous
studies pointing in the same direction.33e35 The assessment
of sCD25 and sCD163 is already used in the diagnosis and
follow-up of Hemophagocytic Lymphohistiocytosis (HLH)
disease activity,36 and given that HLH and septic patients
share many clinical features, their use in sepsis diagnosis
should not be discarded.37 In fact, recent studies suggest
that sCD163 and sCD25 could be promising markers in sepsis
research,38,39 and our results support this hypothesis.
Moreover, the pro-inflammatory cytokines IL-6 and IL-18
were significantly increased in the septic patient group.
This result is in agreement with their role in sepsis, already
pinpointed previously.40
Finally, Gene Ontology analysis of the combined results
from both proteomics and ELISA revealed that the ten
proteins included in the study (AT-III, CLUS, SAA-1, HO-1,
IL-6, IL-18, sCD25, sCD163, sICAM-1 and sFas) are at least
partially biologically connected as a group, and play a role
mainly in the activation of the immune response, inflam-
matory response and response to wounding. As these
markers are not sepsis specific, and changes in serum levels
may be observed in other diseases (e.g. cancer), further
Table 3 Validation of the 2DE results and the analysis of inflammation related proteins in septic patients and healthy donors’
sera by ELISA assays.
Protein
(units)
Protein ID
(Uniprot)
Controls Patients
na Median of
concentration
Range of
concentration
na Median of
concentration
Range of
concentration
2D validation
results
AT-III (mg/ml) P01008 56 294.80* 192.80e438.80 62 217.50* 71.40e527.10
CLUS (mg/ml) P10909 35 45.10* 29.59e72.96 36 31.03* 7.21e77.86
SAA-1 (ng/ml) P0DJI8 43 2607.00* 320.75e19,692.00 46 74,404.00* 4208.00e174,512.00
Classical
Inflammation
CD163 (ng/ml) Q86VB7 60 634.87* 314.49e1426.72 62 1651.95* 499.17e3672.27
HO-1 (ng/ml) P09601 62 0.25* 0.2530e1.64 64 0.42* 0.25e19.09
ICAM-1 (ng/ml) P05362 61 207.58* 141.86e472.18 70 579.46* 199.80e1883.96
IL-6 (pg/ml) P05231 55 0.74* 0e611.62 60 51.69* 0e505.46
IL-18 (pg/ml) Q14116 59 16.76* 12.67e242.36 66 31.02* 12.67e1201.16
sCD25 (pg/ml) P01589 60 844.42* 363.04e1734.55 56 4072.68* 214.59e39,720.21
sFAS (pg/ml) P25445 61 3545.29* 1810.36e5414.05 67 4437.26* 1092.68e22,918.08
a The number of individuals used in each analysis.
* Independent Median Test p < 0.01.
Serum protein markers and their validation in sepsis 471comparative studies would be very interesting in the
future.
This work provides an interesting insight into the dis-
covery of sepsis biomarkers based on the identification of a
panel of deregulated serum proteins in patients diagnosed
with sepsis. We show a set of ten proteins (AT-III, CLUS,
SAA-1, HO-1, IL-6, IL-18, sCD25, sCD163, sICAM-1 and sFas)
that seem to be crucial in the pathogenesis and may
potentially work as a complementary tool for the physician
in the diagnosis of sepsis. The correlation of these ten
markers with other biomarkers and clinical features, and
clinical validation follow-up are needed for a more
comprehensive characterization. In addition, further ana-
lyses should provide a better understanding of the role of
these proteins in the pathophysiology of the disease and
may increase the list of molecules susceptible of being
helpful for sepsis diagnosis and treatment.
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